Iwilfin (eflornithine tablets - US WorldMeds) — Cigna

Initial criteria

• Patient has high-risk disease; AND
• The medication is being used to reduce the risk of relapse; AND
• Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy (e.g., Unituxin [dinutuximab intravenous infusion])

Approval duration

1 year